Project

Development of in-vivo relevant dissolution systems for selected neglected-diseases medicines

Code
01W03714
Duration
01 August 2014 → 30 September 2020
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Natural sciences
    • Scientific computing
    • Bioinformatics and computational biology
  • Medical and health sciences
    • Bioinformatics and computational biology
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Tropical medicine
    • Other basic sciences
    • Bioinformatics and computational biology
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Tropical medicine
    • Other clinical sciences
    • Public health care
    • Public health services
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Biomarker discovery and evaluation
    • Drug discovery and development
    • Medicinal products
    • Pharmaceutics
    • Pharmacognosy and phytochemistry
    • Pharmacology
    • Pharmacotherapy
    • Toxicology and toxinology
    • Other pharmaceutical sciences
    • Bioinformatics and computational biology
    • Laboratory medicine
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Tropical medicine
    • Other translational sciences
    • Other medical and health sciences
  • Engineering and technology
    • Chemical product design and formulation
    • Biomaterials engineering
    • Scientific computing
Keywords
antimalaria biorelevant dissolution pharmaceutical quality IVIVR neglected diseases anthelmintics tablets substandard medicines
 
Project description

Functional in-vitro dissolution systems for selected antimalaria and anthelmintic medicines will be developed using biorelevant media and hydrodynamics to dissolve the active drug from the tablet, coupled to caco-2 and parasites to quantify the diffusion permeability. A global IVIV model will be developed, and verified by in-vivo pharmacokinetics.